Compare CVS Health Corp (CVS) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Snowflake Inc — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while Snowflake Inc trades at $276.98 (market cap $95.64B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 2.51% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| CVS | SNOW | |
|---|---|---|
Market Cap | $135.48B | $95.64B |
Sector | Health | Technology |
52-Week High | $106.18 | $280.16 |
52-Week Low | $58.75 | $121.11 |
Enterprise Value | $202.02B | $95.46B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Snowflake (SNOW) trades at $268.65, up 2.75% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though remains unprofitable with a -23.79% net margin. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.39 surpassing the $0.3193 estimate. Analyst sentiment remains overwhelmingly positive with 42 buy ratings and a $297.35 consensus price target, representing 10.7% upside potential.
Snowflake's outlook remains promising due to accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces risks from premium valuation (P/S 18.19), intense cloud competition, and persistent profitability challenges. The stock's current technical positioning near pivot point resistance at $269 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
